* Phathom Pharmaceuticals Inc PHAT.OQ PHAT.O is expected
to show a rise in quarterly revenue when it reports results on
May 9 for the period ending March 31 2024
* The Florham Park New Jersey-based company is expected to
report
revenue of $2.047 million, according to the mean estimate from 8
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Phathom Pharmaceuticals
Inc is
for a loss of $1.31 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Phathom
Pharmaceuticals Inc is $25.00, above its last closing price
of $10.84.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -1.10 -1.08 -1.39 Missed -29.1
Sep. 30 0001 -0.87 -0.89 -0.76 Beat 14.7
Jun. 30 2023 -0.94 -0.98 -0.84 Beat 14.2
Mar. 31 2023 -1.23 -1.26 -0.89 Beat 29.4
Dec. -1.34 -1.35 -1.33 Beat 1.6
31 2022
Sep. 30 2022 -1.32 -1.32 -1.32 Met -0.2
Jun. 30 2022 -0.99 -1.03 -1.33 Missed -29.1
Mar. 31 2022 -0.98 -0.97 -1.07 Missed -10.5
This summary was machine generated May 7 at 14:43 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)